Capital Warden

$QS 👀 fantastic write up on QuantumScape and the age of solid state batteries upon us soon! Def. worth a read!

$OKLO sold off with the $XE IPO hype - now trading around the same mcap. Doesn’t really make sense. → Earlier timeline  • OKLO: criticality ~2026 → power ~2027  • XE: still licensing → deployment ~2029–2030 → Backed by Sam Altman → NVIDIA partnership → a more scalable model of build/own/operate Sell-off was a buying opportunity. First criticality targeted ~mid-2026 - biggest inflection trigger for OKLO.

$QS Swing Trade Idea 💡💡💡 This can give a great swing opportunity IMO. Quantum Scape (QS) develops next-generation, solid-state lithium-metal batteries for electric vehicles (EVs) designed to offer faster charging, higher energy density, and greater safety compared to conventional lithium-ion batteries. This is in my top watchlist here. If you can see in Sep, 2025 it made a similar 30% gap up move and gave up entire move next few days and then went on to run 116% in just couple of months. I am seeing same pattern repeating here.. We saw a huge surge in volume and price, but giving up entire move again. But as long as its above $6.8 ( all key moving averages), This can still have its run. I am going to take a position here this week. Battery stocks will have their run again. $EOSE $FLNC $AMPX $ENVX $SLDP $ALB

@planert41 Lot of aggressive calls stacking here, especially near-term. Looks like they’re betting on a quick move up → could get spicy if momentum hits.

$QS check

$BB is an underappreciated robotics play via QNX → a OS already used in auto + medical + industrial systems. As Tesla scales robotics, the TAM expands much faster than most expect . QNX is already embedded in the systems that need to run safely + reliably at scale → well positioned as robotics moves mainstream.

Added $QS today. I see this approaching the inflection phase with its revolutionary solid-state battery tech. • Eagle Line up and running → QSE-5 cells coming off a real pilot line • First customer billings (Murata, Corning) → revenue has started • OEM traction → 2 JDAs + another Top-10 moving into joint development • Data center angle emerging (800V / in-rack power) Closing in on inflection. Rerates follow.

$OKLO is HOT right now. 🔥 The rerate is just starting, and this company just keeps delivering. They just announced a massive partnership with $NVDA and Los Alamos National Lab to advance nuclear-powered AI factories. ☢️🤝🤖 Extremely bullish. The future of AI needs nuclear power, and Oklo is bringing it! barrons.com/articles/oklo-…

$OKLO - HSBC initiates with a Buy - PT $96 ⠀ • Targeting July ’26 first criticality → key inflection / major derisking • Build-own-operate model = recurring, long-term power revenue • DOE-backed projects + early demand pipeline forming • ~$2.5B cash, no debt → funded through initial rollout As it continues to derisk, expect PTs to move higher - rerate follows.

Doubled my position in $BB today. QNX is embedded in the next wave of software-defined vehicles, the NVIDIA IGX integration opens the door to robotics/industrial AI, and recurring software revenue is starting to inflect. Rerate has just started.

What a day for $OKLO - feels like just the beginning. Still early in the rerate as the story continues to derisk ☢️

$OKLO just completed its Groves test site build in Idaho for the test reactor. Next step is first criticality - the key real-world validation of the design - targeted for July ‘26. ~7 months from ground to finished structure. If they hit it, 2028 commercialization path gets meaningfully clearer. Big catalyst ahead, thesis continuing to de-risk.

Been adding $OKLO as I believe a nuclear bull market is beginning, with regulatory tailwinds and OKLO starting to execute adding to the move. Into ‘26 I’m watching: • Atomic Alchemy - license is in place. First isotope sales would be the transition from pre-revenue to actual revenue • July ‘26 criticality - Idaho test reactor reaching first reaction. This is a key validation point for the build schedule and commercial pathway into 2028 • DOE pathway - already allowing parts of the program to move through faster federal authorization versus traditional NRC timelines. This is a material tailwind for any commercial rollout moving from ~10–15 years historically toward ~2–3 year type timelines • NRC Part 53 - a new NRC framework moving licensing from rigid legacy rules toward a risk-based approach that could reduce friction for advanced reactors if implemented as intended. • Ohio/Meta - Pike County site progression is the foundation for the 1.2GW scale assumption into 2028 If these continue to progress, 2028 transitions from a long-dated assumption into something the market can start pricing forward.

Is $BB finally starting to rerate on fundamentals? QNX + NVDA IGX Thor + push into robotics/industrial automation… feels like the pivot might actually be working. Started a position a few days ago.

Current portfolio. High conviction, high potential plays for 2026: 1. $HIMS - Telehealth leader; peptide expansion is officially in motion as the FDA begins easing restrictions. 2. $GLXY - Prime digital asset leader and datacenter play. 3. $PGY - AI-driven fintech disrupting the credit markets. 4. $FUBO - Massive Disney synergy & growth potential following the Hulu integration. 5. $TE - Capitalizing on the surge in domestic US solar growth & infrastructure. 6. $OKLO - Leading the charge in small nuclear (SMR) tech for clean energy.

$GLXY @galaxyhq #DataCenterBusiness #Helios Let me share me with you that Galaxy has officially filed/begun with the Helios Phase 2 which is devided into three different sub-projects.Two habe already started. I expect an official announcement on the upcoming earnings call 📢

$HIMS Doesn’t get any more textbook than that. Typical wave 2 bull flag and BANG- Wave 3 is underway! You’ll see $40 EASILY in the next little bit here.

$HIMS with an amazing day yesterday up almost 25% Price is obviously in wave 3 now and is headed to the $41 target This move came from RFK Jr discussing loosening some restrictions on certain peptides $HIMS is one of the only companies with a peptide manufacturing facility I think we're still early here... nfa

$HIMS Everyone knows Ozempic now. It peaked mid-2024 and became a household name. You can ask almost anyone and they’ll know what it is or at least what it does. Now look at “peptides.” Most people you know have no idea what that even means. Ask someone close to you. They won’t have a clue. But search interest is telling you something very different. It’s accelerating fast and is now approaching where Ozempic was at peak attention. Peptides are short chains of amino acids that influence specific biological pathways. They can target fat loss, muscle growth, recovery, inflammation, and longevity. The scope is broad and still evolving. It is early, fragmented, and not yet understood by the public. Which is exactly why the opportunity exists. That’s where HIMS comes in. They’ve already proven they can take a stigmatized or complex category and make it simple, accessible, and consumer-friendly at scale. They did it with hair loss. They did it with ED. They are doing it with weight loss. When peptides move from niche/black market to mainstream, HIMS is one of the few platforms positioned to capture that demand early and package it for the mass market. You don’t need to guess if people are interested. Search is already telling you. Ozempic is already a household name. Peptides are next.

@CaesarCapitalz Same! 👌🏻

I’m back in the green on my $HIMS position 🥳

@growthrapidly $45

$HIMS How much do you think HIMS will trade at next week? 👀